^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EVX-02

    i
    Other names: EVX-02
    Associations

    News

    Trials
    Company:
    Evaxion
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    3ms
    Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 (clinicaltrials.gov)
    P1/2, N=15, Terminated, Evaxion Biotech A/S | Active, not recruiting --> Terminated; Based on the promising interim results of study part 1, it was decided to further accelerate the development of the 2nd generation DNA plasmid immunotherapy. Therefore enrolment of patients was completed after study part 1
    Trial termination • Metastases
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    EVX-02
    almost2years
    Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 (clinicaltrials.gov)
    P1/2, N=15, Active, not recruiting, Evaxion Biotech A/S | Recruiting --> Active, not recruiting | N=46 --> 15 | Trial completion date: Jul 2026 --> Mar 2023 | Trial primary completion date: Mar 2024 --> Mar 2023
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    EVX-02
    over3years
    Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 (clinicaltrials.gov)
    P1/2, N=46, Recruiting, Evaxion Biotech A/S | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    EVX-02
    almost4years
    Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 (clinicaltrials.gov)
    P1/2, N=46, Not yet recruiting, Evaxion Biotech ApS
    Clinical • New P1/2 trial
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    EVX-02